Edition:
United States

Profile: MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

5.54EUR
22 Feb 2017
Change (% chg)

€-0.02 (-0.36%)
Prev Close
€5.56
Open
€5.58
Day's High
€5.63
Day's Low
€5.33
Volume
533,973
Avg. Vol
199,214
52-wk High
€5.63
52-wk Low
€2.80

MDxHealth SA is a Belgium-based company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. The Company’s offerings are structured into two divisions: Clinical Molecular Diagnostics (ClinicalMDx) solutions, providing physicians with tests which aid in the identification and treatment of their cancer patients, and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions, collaborating with pharmaceutical companies on the development of companion diagnostics, biomarker discovery, and clinical trial testing. Its ClinicalMDx solutions include four different product types: ConfirmMDx, InformMDx, RecurMDx and PredictMDx. MDxHealth‘s PharmacoMDx services, provided to both existing collaborators and on contracted services basis, focus on the identification and development of epigenetic biomarkers and molecular tests into companion diagnostics. The Company has one wholly owned subsidiary, MDxHealth Inc.

Company Address

MDxHealth SA

CAP Business Center, Rue d'Abhoo
HERSTAL     4040
P: +324.3642070
F: +324.3642071

Company Web Links